Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice

BMC Cardiovascular Disorders

Kanneboyina Nagaraju¹  Eric P Hoffman¹  Jack H van der Meulen¹  Arpana Sali¹  Qing Yu¹  Alfredo D Guerron¹  Christopher F Spurney¹ 

[1] Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC USA

关键词: isoproterenol;    cardiomyopathy;    poloxamer;    mdx;    Duchenne muscular dystrophy;   

Others  :  1086072
DOI  :  10.1186/1471-2261-11-20

 received in 2011-01-04, accepted in 2011-05-16,  发布年份 2011

【 摘 要 】

Background

Cardiomyopathy in Duchenne muscular dystrophy (DMD) is an increasing cause of death in patients. The absence of dystrophin leads to loss of membrane integrity, cell death and fibrosis in cardiac muscle. Treatment of cardiomyocyte membrane instability could help prevent cardiomyopathy.

Methods

Three month old female mdx mice were exposed to the β₁ receptor agonist isoproterenol subcutaneously and treated with the non-ionic tri-block copolymer Poloxamer P188 (P188) (460 mg/kg/dose i.p. daily). Cardiac function was assessed using high frequency echocardiography. Tissue was evaluated with Evans Blue Dye (EBD) and picrosirius red staining.

Results

BL10 control mice tolerated 30 mg/kg/day of isoproterenol for 4 weeks while death occurred in mdx mice at 30, 15, 10, 5 and 1 mg/kg/day within 24 hours. Mdx mice tolerated a low dose of 0.5 mg/kg/day. Isoproterenol exposed mdx mice showed significantly increased heart rates (p < 0.02) and cardiac fibrosis (p < 0.01) over 4 weeks compared to unexposed controls. P188 treatment of mdx mice significantly increased heart rate (median 593 vs. 667 bpm; p < 0.001) after 2 weeks and prevented a decrease in cardiac function in isoproterenol exposed mice (Shortening Fraction = 46 ± 6% vs. 35 ± 6%; p = 0.007) after 4 weeks. P188 treated mdx mice did not show significant differences in cardiac fibrosis, but demonstrated significantly increased EBD positive fibers.

Conclusions

This model suggests that chronic intermittent intraperitoneal P188 treatment can prevent isoproterenol induced cardiomyopathy in dystrophin deficient mdx mice.

【 授权许可】

   
2011 Spurney et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gulati S, Saxena A, Kumar V, Kalra V: Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr 2005, 72(5):389-393.
• [2]Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS: Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 2004, 14(8-9):491-496.
• [3]Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, Hoffman EP: Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 2008, 18(5):371-381.
• [4]Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, Nagaraju K: Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009, 39(5):591-602.
• [5]Kamogawa Y, Biro S, Maeda M, Setoguchi M, Hirakawa T, Yoshida H, Tei C: Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. Cardiovasc Res 2001, 50(3):509-515.
• [6]Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, Petrof BJ: Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 2001, 15(9):1655-1657.
• [7]Buyse GM, Van der Mieren G, Erb M, D'Hooge J, Herijgers P, Verbeken E, Jara A, Van Den Bergh A, Mertens L, Courdier-Fruh I, Barzaghi P, Meier T: Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 2009, 30(1):116-124.
• [8]Van Erp C, Irwin NG, Hoey AJ: Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006, 34(3):327-334.
• [9]Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM: Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005, 436(7053):1025-1029.
• [10]Yue Y, Skimming JW, Liu M, Strawn T, Duan D: Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet 2004, 13(15):1669-1675.
• [11]Ballas SK, Files B, Luchtman-Jones L, Benjamin L, Swerdlow P, Hilliard L, Coates T, Abboud M, Wojtowicz-Praga S, Grindel JM: Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 2004, 28(2):85-102.
• [12]Lee RC, River LP, Pan FS, Ji L, Wollmann RL: Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad Sci USA 1992, 89(10):4524-4528.
• [13]Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Nagaraju K: Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 2011, 16(1):87-95.
• [14]Brooks SV, Faulkner JA: Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 1988, 404:71-82.
• [15]Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN: Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004, 24(19):8467-8476.
• [16]Frey N, Barrientos T, Shelton JM, Frank D, Rutten H, Gehring D, Kuhn C, Lutz M, Rothermel B, Bassel-Duby R, Richardson JA, Katus HA, Hill JA, Olson EN: Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med 2004, 10(12):1336-1343.
• [17]Keys JR, Greene EA, Cooper CJ, Naga Prasad SV, Rockman HA, Koch WJ: Cardiac hypertrophy and altered beta-adrenergic signaling in transgenic mice that express the amino terminus of beta-ARK1. Am J Physiol Heart Circ Physiol 2003, 285(5):H2201-2211.
• [18]Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF: Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 2003, 278(48):47694-47699.
• [19]Emanuele RM: FLOCOR: a new anti-adhesive, rheologic agent. Expert Opin Investig Drugs 1998, 7(7):1193-1200.
• [20]Gibbs WJ, Hagemann TM: Purified poloxamer 188 for sickle cell vaso-occlusive crisis. Ann Pharmacother 2004, 38(2):320-324.
• [21]Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay JN, Metzger JM: Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010, 120(4):1140-1150.
• [22]Quinlan JG, Wong BL, Niemeier RT, McCullough AS, Levin L, Emanuele M: Poloxamer 188 failed to prevent exercise-induced membrane breakdown in mdx skeletal muscle fibers. Neuromuscul Disord 2006, 16(12):855-864.
• [23]Townsend D, Yasuda S, Metzger J: Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach. Expert Rev Cardiovasc Ther 2007, 5(1):99-109.
• [24]Loufrani L, Levy BI, Henrion D: Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ Res 2002, 91(12):1183-1189.
• [25]Loufrani L, Matrougui K, Gorny D, Duriez M, Blanc I, Levy BI, Henrion D: Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 2001, 103(6):864-870.
• [26]Ng R, Metzger JM, Claflin DR, Faulkner JA: Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. Am J Physiol Cell Physiol 2008, 295(1):C146-150.
• [27]Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM: Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 2008, 16(5):832-835.